Drugs for some common eye disorders.
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D018679:Cholinergic Agonists / Q000627:therapeutic use; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D003234:Conjunctivitis, Bacterial / Q000188:drug therapy*; D016572:Cyclosporine / Q000627:therapeutic use; D004234:Diuretics, Osmotic / Q000627:therapeutic use; D015352:Dry Eye Syndromes / Q000188:drug therapy*; D005128:Eye Diseases / Q000188:drug therapy; D005901:Glaucoma / Q000188:drug therapy*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008268:Macular Degeneration / Q000188:drug therapy* / Q000628:therapy; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D010349:Patient Compliance; D018579:Patient Selection; D010778:Photochemotherapy; D011453:Prostaglandins / Q000627:therapeutic use; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D015032:Zinc / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000975:Antioxidants; D002257:Carbonic Anhydrase Inhibitors; D018679:Cholinergic Agonists; D004234:Diuretics, Osmotic; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D011453:Prostaglandins; D042461:Vascular Endothelial Growth Factor A; D016572:Cyclosporine; D014222:Triamcinolone Acetonide; D015032:Zinc